FindTrial
Sign In

Understanding the patient profile for Methylcobalamin, duloxetine and pregabalin combination, in Indian patients with Diabetes related neuropathic pain

A retrospective multicentre observational study to assess the patient profile for the fixed dose combination of Methylcobalamin, duloxetine and pregabalin, in Indian patients with Diabetic Peripheral Neuropathy - (BLUE FEATHER DPN) - BLUE FEATHER DPN

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/101593
Enrollment
12500
Registered
2026-01-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

Intervention1: Nil: Nil

Sponsors

Torrent Pharmaceuticals Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with Diabetic Peripheral Neuropathy 2. Patients who were prescribed FDC of Pregabalin, Duloxetine, Methylcobalamin FDCs (any dosage)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
1. To understand epidemiological profile of patients of diabetic peripheral neuropathy, na ve or switching over to Pregabalin, Duloxetine & Methylcobalamin FDCsTimepoint: Baseline—

Secondary

MeasureTime frame
1. Percentage of new patients who were prescribed triple FDC 2. Percentage of patients on monotherapy switched over to triple FDC & switched from which therapy 3. Percentage of patients on dual therapy switched over to triple FDC & switched from which therapyTimepoint: Baseline—

Countries

India

Contacts

Public ContactNarendra Chouksey

Torrent Pharmaceuticals Ltd.

LokeshRV@torrentpharma.com917069000601

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026